Lipella Pharmaceuticals Inc (LIPO) - News Archive

Lipella Pharmaceuticals Advances in Oral Lichen Planus Treatment and Bladder Imaging Technology Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has announced significant advancements in its clinical tri...

Lipella Pharmaceuticals Faces Financial Challenges Amid Promising Drug DevelopmentIn a recent appearance on the Pharmaverse podcast, Michael Chancellor, co-founder of Lipella Pharmaceuticals, discussed the company’s inn...

Lipella Pharmaceuticals recently announced the successful completion of the first cohort in its Phase 2a clinical trial investigating LP-310, a novel therapeutic candidate aimed at treating oral lichen planus (OLP). Fol...

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) has announced promising early results from its Phase 2a clinical trial of LP-310, a novel treatment for Oral Lichen Planus (OLP). The study, which primarily focuses on the tol...

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference Lipella Pharmaceuticals Inc., a leading innovator in urological health, has announced a breakthrough in bladder imaging technology a...

Pittsburgh, PA October 2023 Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has successfully dosed the first two patients in its eagerly anticipated Phase 2a clinical trial for the treatment of Oral Lic...

Lipella Pharmaceuticals has officially commenced its Phase 2a clinical trial for LP-310, a potential treatment aimed at alleviating Oral Lichen Planus (OLP). This development marks a significant step forward in the ques...

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus: A Promising Step ForwardLipella Pharmaceuticals, a biopharmaceutical company committed to bringin...

Groundbreaking Developments at Lipella Pharmaceuticals: Upcoming ASCO Presentation and FDA Type C Meeting Lipella Pharmaceuticals, a clinical-stage biotechnology company dedicated to the development of innovative treatm...

In a recent announcement by Lipella Pharmaceuticals, the esteemed biopharmaceutical company highlighted plans to publish an abstract detailing substantial preclinical support for its new product candidate. The abstract...

Lipella Pharmaceuticals Advances Promising Treatment for Hemorrhagic Cystitis as FDA Grants Type C Meeting Hemorrhagic cystitis, a distressing condition characterized by inflammation and bleeding in the bladder, affects...

In a recent press release, Lipella Pharmaceuticals announced the Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) for LP-410, a potential breakthrough treatment for oral Graft-Versus-Host D...